Kılıçkaya Refika, Güleç Ersel, Ünlügenç Hakkı, Gündüz Murat, Işık Geylan
Department of Anaesthesiology, Çukurova University Faculty of Medicine, Adana, Turkey.
Turk J Anaesthesiol Reanim. 2015 Jun;43(3):174-80. doi: 10.5152/TJAR.2015.15013. Epub 2015 Feb 16.
This study was designed to compare the effects of dexketoprofen, lornoxicam, and diclophenac sodium on postoperative analgesia and tramadol consumption in patients receiving postoperative patient-controlled tramadol after a major abdominal surgery.
Eighty patients were randomized to receive one of the four study drugs. Patients in group dexketoprofen (DT) received IV 50 mg dexketoprofen, group lornoxicam (LR) received IV 8 mg lornoxicam, group diclophenac sodium (DS) received 75 mg IV diclophenac sodium and group saline (S) received 0.9% saline in 2 mL syringes, 20 min before the end of anaesthesia. A standardized (1 mg kg(-1)) dose of tramadol was routinely administered to all patients as the loading dose at the end of surgery. Postoperatively, whenever patients requested, they were allowed to use a tramadol patient-controlled analgesia device giving a bolus dose (0.2 mg kg(-1)) of tramadol. Pain, discomfort, and sedation scores, cumulative tramadol consumption, supplemental meperidine requirement, and side effects were recorded.
Visual rating scale and patient discomfort scores were significantly lower in DT, LR and DS groups compared to those in in group S (p<0.001). Cumulative tramadol consumption was significantly lower in non-steroidal anti-inflammatory drug (NSAID)-treated groups at each study period after the second postoperative hour than in group S (p<0.001). Supplemental meperidine requirement was significantly higher in group S at each study period after postoperative 30 min than in NSAID-treated groups (p<0.01).
After major abdominal surgery, adding IV diclophenac, lornoxicam or dexketoprofen to patient-controlled tramadol resulted in lower pain scores, smaller tramadol consumption, less rescue supplemental analgesic requirement, and fewer side effects compared with the tramadol alone group.
本研究旨在比较右酮洛芬、氯诺昔康和双氯芬酸钠对接受腹部大手术后使用曲马多患者自控镇痛的患者术后镇痛效果及曲马多用量的影响。
80例患者随机接受四种研究药物之一。右酮洛芬组(DT)静脉注射50mg右酮洛芬,氯诺昔康组(LR)静脉注射8mg氯诺昔康,双氯芬酸钠组(DS)静脉注射75mg双氯芬酸钠,生理盐水组(S)在麻醉结束前20分钟接受2ml注射器中的0.9%生理盐水。所有患者在手术结束时常规给予标准化剂量(1mg·kg⁻¹)的曲马多作为负荷剂量。术后,患者如有需要,可使用曲马多患者自控镇痛装置,给予负荷剂量(0.2mg·kg⁻¹)的曲马多。记录疼痛、不适和镇静评分、曲马多累计用量、补充哌替啶需求量及副作用。
与S组相比,DT组、LR组和DS组的视觉评分量表和患者不适评分显著更低(p<0.001)。在术后第二小时后的每个研究时间段,非甾体抗炎药(NSAID)治疗组的曲马多累计用量显著低于S组(p<0.001)。术后30分钟后的每个研究时间段,S组的补充哌替啶需求量显著高于NSAID治疗组(p<0.01)。
腹部大手术后,与单纯曲马多组相比,在曲马多患者自控镇痛中添加静脉注射双氯芬酸、氯诺昔康或右酮洛芬可降低疼痛评分、减少曲马多用量、减少补救性补充镇痛需求并减少副作用。